Kaposiform lymphangiomatosis treated with multimodal therapy improves coagulopathy and reduces blood angiopoietin‐2 levels

J Crane, J Manfredo, E Boscolo, M Coyan… - Pediatric blood & …, 2020 - Wiley Online Library
J Crane, J Manfredo, E Boscolo, M Coyan, C Takemoto, M Itkin, DM Adams, TD Le Cras
Pediatric blood & cancer, 2020Wiley Online Library
Kaposiform lymphangiomatosis (KLA) is a rare, life‐threatening congenital lymphatic
malformation. Diagnosis is often delayed due to complex indistinct symptoms. Blood
angiopoietin‐2 (ANG2) levels are elevated in KLA and may be useful as a biomarker to
monitor disease status. We report a 7‐year‐old male child with easy bruising, inguinal
swelling, and consumptive coagulopathy, diagnosed with KLA. A multimodal treatment
regimen of prednisone, sirolimus, vincristine, and adjunctive zoledronate was used. Plasma …
Abstract
Kaposiform lymphangiomatosis (KLA) is a rare, life‐threatening congenital lymphatic malformation. Diagnosis is often delayed due to complex indistinct symptoms. Blood angiopoietin‐2 (ANG2) levels are elevated in KLA and may be useful as a biomarker to monitor disease status. We report a 7‐year‐old male child with easy bruising, inguinal swelling, and consumptive coagulopathy, diagnosed with KLA. A multimodal treatment regimen of prednisone, sirolimus, vincristine, and adjunctive zoledronate was used. Plasma ANG2 levels were highly elevated at diagnosis but decreased during treatment. The patient showed significant clinical improvement over a 38‐month period and normalization of ANG2 levels correlated with resolution of the coagulopathy.
Wiley Online Library